Intellia identifies genetic risk factor for liver complications in CRISPR trialnews2026-08-06T15:33:40+00:00August 6th, 2026|Endpoints News|
J&J lines up $2.58B option to buy Sail, Flagship’s in vivo CAR-T biotechnews2026-07-30T04:32:19+00:00July 30th, 2026|Endpoints News|
Broad Institute launches Center for Therapeutic Genetics for rare diseasesnews2026-07-21T12:00:45+00:00July 21st, 2026|Endpoints News|
Nava Therapeutics emerges with $89M for lipid nanoparticlesnews2026-07-15T13:00:03+00:00July 15th, 2026|Endpoints News|
The data that led Cellular Intelligence to pick up Novo’s Parkinson’s stem cell therapynews2026-07-10T11:00:24+00:00July 10th, 2026|Endpoints News|
ARPA-H bookmarks $160M for custom gene editing treatments. Is it enough?news2026-07-09T19:20:51+00:00July 9th, 2026|Endpoints News|
French gene therapy biotech gets €33M to follow Krystal’s blueprintnews2026-07-07T05:30:37+00:00July 7th, 2026|Endpoints News|
FDA approves Orca Bio’s cell therapy to improve transplant outcomesnews2026-07-01T15:44:25+00:00July 1st, 2026|Endpoints News|
FDA’s acting director of cell and gene therapies to leave positionnews2026-06-30T14:47:37+00:00June 30th, 2026|Endpoints News|
Sangamo’s three-decade run comes to a close as Lilly and Astellas eye assetsnews2026-06-23T15:57:02+00:00June 23rd, 2026|Endpoints News|
